SCHEMBL4837068

SCHEMBL4837068

O=C(C1CCCCC1)N1CCc2ccccc2C1CCN1CCC(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.49
ALDH1A1 P00352 1/20 0.49
DRD2 P14416 2/20 0.48
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRM4 P08173 1/20 0.43
MTNR1B P49286 3/20 0.43
OPRD1 P41143 1/20 0.43
DRD4 P21917 1/20 0.41
GRM2 Q14416 1/20 0.41
CNR1 P21554 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A9 P48067 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
KEAP1 Q14145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839067 1.00 NPSR1 (0.49) NPSR1ALDH1A1DRD2HDAC1HDAC8
SCHEMBL4841324 0.99 DRD2 (0.49) NPSR1ALDH1A1DRD2HDAC1HDAC8
SCHEMBL4836800 0.92 DRD2 (0.47) NPSR1ALDH1A1DRD2HDAC1HDAC8
SCHEMBL4835932 0.88 DRD2 (0.47) NPSR1DRD2HDAC1HDAC8MEN1
SCHEMBL4830056 0.88 NPSR1 (0.49) NPSR1ALDH1A1CHRM4MTNR1BDRD4
SCHEMBL4835975 0.87 NPSR1 (0.57) NPSR1ALDH1A1MTNR1BKEAP1
SCHEMBL4835979 0.87 DRD2 (0.48) DRD2HDAC1HDAC8CHRM4DRD4
SCHEMBL4837124 0.87 DRD2 (0.48) DRD2HDAC1HDAC8CHRM4DRD4
SCHEMBL4830091 0.87 DRD2 (0.47) NPSR1DRD2HDAC1HDAC8MEN1
SCHEMBL4830011 0.87 DRD2 (0.47) DRD2HDAC1HDAC8CHRM4DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 NPSR1 167/4885ALDH1A1 639/4885DRD2 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.